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rch 27, 2013.his study aimed to assess the clinical implications and optimal cutoff value of high platelet reactivity (HPR) in
patients receiving clopidogrel for peripheral endovascular procedures.Background As noted in coronary studies, HPR could be related to increased adverse events.Methods This prospective trial included patients receiving clopidogrel 75 mg daily, before and after infrainguinal angioplasty
or stenting. Platelet inhibition was assessed with the VerifyNow P2Y12 point-of-care test. Primary endpoints were
1-year clinical events rate (composite endpoint of death, major stroke, major amputation, target vessel
revascularization, and bypass) according to the P2Y12 reaction units (PRU)-based quartile distribution, the
estimation of the optimal PRU cutoff value for predicting clinical outcome, and the identiﬁcation of independent
predictors inﬂuencing event-free survival.Results In total, 100 consecutive patients were enrolled. The 1-year cumulative events rate was 4% in the ﬁrst quartile,
12% in the second, 52% in the third, and 84% in the fourth. Pairwise comparisons demonstrated a signiﬁcant
difference in the composite endpoint between successive quartiles (all p < 0.05 except for the ﬁrst vs. second
quartile). According to receiver-operating characteristic curve analysis, the optimal cutoff value for the composite
endpoint was PRU 234 (area under the curve: 0.883; 95% conﬁdence interval [CI]: 0.811 to 0.954; p < 0.0001;
sensitivity: 92.1%; speciﬁcity: 84.2%). Cox multivariate regression analysis identiﬁed HPR (PRU 234) as the only
independent predictor of an increased number of adverse events (hazard ratio: 16.9; 95% CI: 5 to 55; p < 0.0001).Conclusions On-treatment HPR is associated with markedly increased adverse clinical events in patients undergoing peripheral
endovascular procedures. Point-of-care clopidogrel assessment might be useful in individualizing antiplatelet
therapy to attain superior clinical results. (High On-Treatment Platelet Reactivity Following Peripheral Endovascular
Procedures [PRECLOP]; NCT01744613) (J Am Coll Cardiol 2013;61:2428–34) ª 2013 by the American College
of Cardiology FoundationPlatelets play a key role in the development of thrombotic
complications in patients with documented atherosclerotic
vascular disease, including those with coronary artery
disease, cerebrovascular disease, and peripheral arterial
disease (PAD) (1,2). Therefore, oral antiplatelet drug
therapy with aspirin and clopidogrel is the cornerstone
therapy in a variety of conditions characterized by the risk for
arterial thrombosis (3,4).
Despite the high initial success rate of percutaneous
coronary intervention (PCI), some patients will developal Radiology, Patras University Hospital, Rio,
hat they have no relationships relevant to the
3; revised manuscript received March 24, 2013,recurrent ischemic events due to stent restenosis/thrombosis,
regardless of dual antiplatelet treatment (5,6). Moreover,
the wide interindividual variability in the inhibitory effect
of clopidogrel on platelet aggregation has been also widely
established (7,8). Numerous studies have correlated on-
treatment high platelet reactivity (HPR) resulting from
low response to clopidogrel with an increased risk for
cardiovascular events (9,10). This inadequate response to
clopidogrel could be attributed to poor compliance to
treatment, variable absorption of the drug and/or variable
generation of the active metabolite, and various drug–drug
interactions (11,12).
Platelet reactivity has been historically measured with
light-transmittance aggregometry (LTA), but this method is
technically complex and time-consuming (13). Therefore,
Figure 1 Study Flowchart
Patient recruitment and reasons of exclusion, with a ﬁnal target sample of
100 cases at 1 year.
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2429several more practical, point-of care tests have been devel-
oped and are commonly used to assess a patient’s response
to clopidogrel. Among these tests, VerifyNow (Accumetrics
Inc., San Diego, California), a genuine point-of-care assay
that measures platelet-induced aggregation and expresses the
results as platelet P2Y12 reaction units (PRU), has been
described as having advantages such as simplicity, speed, and
user-friendliness (14,15). Published studies using this in-
strument (16,17) have investigated the relationship between
HPR and long-term cardiovascular events after PCI and
have derived an optimal PRU cutoff value to identify
patients at risk for future ischemic events (18). However,
there is a lack of knowledge on the possible correlation
between HPR in patients receiving clopidogrel and adverse
outcomes after peripheral endovascular procedures (PEPs)
(19). Recently, Tepe et al. (20), in a study demonstrating
the short-term superiority of dual antiplatelet therapy
following infrainguinal angioplasty, also reported a trend of
low responsiveness in patients receiving clopidogrel after
endovascular treatment of PAD. We designed the PRE-
CLOP (Platelet Responsiveness to Clopidogrel Treatment
After PEPs) study, using the VerifyNow test, to pro-
spectively evaluate levels of platelet reactivity that may
correlate with adverse clinical events and to create a clini-
cally meaningful cutoff value of platelet inhibition in
patients with PAD treated with infrainguinal angioplasty
or stenting.
Methods
This prospective, single-center study was approved by the
Scientiﬁc and Ethics Committee at Patras University (Rio,
Greece) and was registered in a dedicated electronic database
(NCT01744613). The study included patients scheduled to
undergo a percutaneous angioplasty or stenting procedure
for the treatment of femoropopliteal PAD. All patients
received dual antiplatelet therapy with clopidogrel 75 mg
daily for at least 1 month prior to the procedure. Dual
antiplatelet therapy with clopidogrel 75 mg and aspirin 100
mg daily was then prescribed for 6 months after the
procedure, while single antiplatelet therapy with clopidogrel
75 mg daily was continued throughout the follow-up period.
The study included patients from 18 to 84 years of age, with
either severe life-style–limiting intermittent claudication
classiﬁed as Rutherford stage of PAD 3, or critical limb
ischemia (CLI) classiﬁed as Rutherford stages of PAD 4 to
6, due to an angiographically proven femoropopliteal lesion
that was successfully treated with balloon angioplasty or
stenting. Only patients with successful recanalization were
included in the study. Infrapopliteal disease was treated if
deemed necessary. Both de novo and in-stent restenotic
lesions were included. All patients were enrolled after they
signed an appropriate informed-consent form. Exclusion
criteria were procedural technical failure, deﬁned as the
inability to successfully treat the index lesion and/or to
obtain at least one patent straight arterial line to the distalfoot; acute limb ischemia; coag-
ulation disorders; and failure to
comply with the pre- and post-
procedural antiplatelet regimen
(Fig. 1). Clopidogrel respon-
siveness was evaluated using the
VerifyNow P2Y12 assay point-of-
care testing following peripheral
blood sampling during admis-
sion, always before the procedure,
as described elsewhere (21,22).
Endpoints. The study’s primary
endpoints were the 1-year cumu-
lative clinical events rate (com-
posite endpoint of death, bleeding,
major amputation, or clinically
driven target vessel re-intervention [TVR]) in relation to the
quartile distribution of on-treatment platelet responsiveness
to clopidogrel, expressed as platelet reactivity P2Y12 reactive
unites (PRU); the identiﬁcation of any independent
predictors inﬂuencing the event-free survival rate; as well as
the estimation of the optimal cutoff PRU value for the
Figure 2 Statistical Methods
Steps and methods of the statistical analysis employed in the present study.
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2430prediction of clinical outcomes following PEPs. Secondary
endpoints included procedure- and drug-related complica-
tion rates.
Statistical analysis. This was an open-label study; no
blinding or masking was involved in data collection or
analysis. The population was stratiﬁed into quartiles
according to the recorded PRU values, and a cumulative-
events analysis was performed at 1 year. We tested the
null hypothesis that the 1-year composite endpoint of
cumulative adverse clinical events after femoropopliteal
angioplasty or stenting was not inﬂuenced by the quartile
distribution of PRU values. As this study’s population
included patients with either intermittent claudication or
CLI, the 1-year clinical events rate was expected to be
around 40% (23). Preliminary statistical power analysis
estimated that a minimum enrollment of 88 patients would
be required to detect a 20% difference in the 1-year clinical
events rate between the ﬁrst and fourth quartiles (alpha
error: 5%; beta error: 10%). We set a target of 100 patients
to account for any patient dropouts or cases lost to follow-
up. The composite endpoint in the study’s quartiles was
analyzed using the multiple-comparisons chi-square test.
We then assessed the ability of PRU point-of-care exami-
nation to distinguish between patients with and without
clinical events at 1-year follow-up using receiver-operating
characteristic (ROC) curve analysis, and the optimal cutoff
PRU value was determined by estimating the value resulting
in the maximum sum of sensitivity and speciﬁcity (area
under the curve).
Following identiﬁcation of the PRU optimal cutoff
value, a univariate and multivariate stepwise regression
analysis with a Cox proportional hazards regression statis-
tical model was performed in search of independent
predictors of the study’s primary endpoint (Fig. 2).
Patients’ demographics and procedural details are presented
in detail in Table 1. Only covariates with a p value <0.15
according to an exploratory univariate analysis were
included in the multivariate regression model (22).
Dependent variables ﬁnally evaluated by the Cox multi-
variate stepwise regression analysis were diabetes mellitus,
renal disease, hypertension, smoking habit, baseline clinical
symptoms (intermittent claudication or CLI), and PRU
values below or above the cutoff value as determined
by ROC analysis. Cox regression was also employed to
illustrate time-to-event event-free survival in various patient
groups following adjustment for the covariates mentioned.
Variables are reported as mean  SD. Continuous
variables were compared by standard t test if originating
from a normal distribution; alternatively, a nonparametric
test (Mann-Whitney) was used. Group proportions were
compared with the chi-square test or with the Fisher exact
test in cases of small counts of events (n < 5). The thres-
hold for statistical signiﬁcance was established at alpha
<0.05, and 95% conﬁdence intervals (CIs) are reported in
cases of signiﬁcant results. All statistical analyses wereperformed with SPSS version 20.0 (Systat, Inc., Chicago,
Illinois).Results
In total, 100 consecutive patients (71 men; mean age: 68.5 
9.2 years) treated with femoropopliteal percutaneous angio-
plasty or stenting and fulﬁlling the study’s inclusion criteria
were enrolled in the study and distributed in four quartiles
(25 patients each) according to their PRU values (progres-
sively increased PRU values from the ﬁrst to fourth quartiles).
Signiﬁcantly more diabetic patients were included in the third
compared to the ﬁrst quartile, and more smokers were
included in the fourth compared to the ﬁrst quartile. Most of
the treated lesions were classiﬁed as Treatment Assessment
Services for the Courts (TASC) Class II A, whereas TASC II
classiﬁcations of the lesions were similar among the four
quartiles. Patients’ demographic characteristics, lesion char-
acteristics, and procedural details, as well as their quartile-
based comparisons, are analytically demonstrated in Table 1.
Table 1 Quartile Distribution and Univariate Analysis of Patients Demographics and Procedural Details
Variable
Quartile
Total Cohort (n ¼ 100)First (n ¼ 25) Second (n ¼ 25) Third (n ¼ 25) Fourth (n ¼ 25) p Value
Age, yrs 64.0  10.6 69.1  7.8 70.2  9.3 70.6  8.0 0.40 68.5  9.2
Male 21 (84) 21 (84) 20 (80) 19 (76) 0.82 71 (71)
Comorbidity/risk factor
Hypercholesterolemia 22 (88) 18 (72) 20 (80) 16 (64) 0.37 76 (76)
Hypertension 19 (76) 23 (92) 20 (80) 24 (96) 0.13 86 (86)
De novo lesions 19 (76) 20 (80) 18 (72) 19 (76) 0.93 76 (76)
Smoking 14 (56) 22 (88) 15 (60) 23 (92) 0.03 74 (74)
CLI 13 (52) 11 (44) 18 (72) 21 (84) 0.03 70 (70)
Diabetes 9 (36) 13 (52) 19 (76) 16 (64) 0.03 57 (57)
Ischemic heart disease 8 (32) 8 (32) 6 (24) 10 (40) 0.69 32 (32)
Treatment history
Femoropopliteal treatment 25 (100) 25 (100) 25 (100) 25 (100) n/a 100 (100)
Stent placement 19 (76) 19 (76) 20 (80) 21 (84) 0.88 79 (79)
Adjunctive BTK treatment 8 (32) 9 (36) 11 (44) 9 (36) 0.84 37 (37)
Proton-pump inhibitors 8 (32) 7 (28) 8 (32) 4 (16) 0.53 27 (27)
Renal disease 3 (12) 1 (4) 6 (24) 5 (20) 0.20 15 (15)
Lesion length, mm 75.3  52.2 71.5  45.7 76.1  52.4 85.0  47.0 0.34 76.8  49.3
Occlusions 19 (76) 17 (68) 19 (76) 21 (84) 0.62 76 (76)
TASC A 13 12 8 10 0.49 43
TASC B 4 5 7 5 0.76 21
TASC C 5 5 6 5 0.98 21
TASC D 3 3 4 5 0.83 15
Values are mean  SD or n (%).
BTK ¼ below the knee; CLI ¼ critical limb ischemia; TASC ¼ Treatment Assessment Services for the Courts.
Figure 3 Cumulative Adverse Events
Schematic representation of clinical adverse events according to quartile distri-
bution of platelet (P2Y12) reaction units (PRU).
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2431There were 38 adverse clinical events in the total patient
cohort. The majority were TVR events (36 of 38; 94.7%), as
the remaining events included 1 major amputation and
1 death due to major ischemic stroke in patients with PRU
values of 339 and 414, respectively. None of the patients
were lost to follow-up. The 1-year composite endpoints
were 4% (n ¼ 1 of 25 events) in the ﬁrst quartile, 12% (n ¼
3/25 events) in the second quartile, 52% (n ¼ 13 of 25
events) in the third quartile, and 84% (n ¼ 21 of 25 events)
in the fourth quartile. The multiple-comparisons chi-square
test detected a signiﬁcant difference in the distribution of
events among the separate quartiles (p < 0.0001), whereas
pairwise comparisons identiﬁed signiﬁcantly fewer events in
the ﬁrst versus the third quartile (p < 0.0001), ﬁrst versus
fourth (p < 0.0001), second versus third (p ¼ 0.0012),
second versus fourth (p < 0.0001), and third versus fourth
(p ¼ 0.007). There was no signiﬁcant difference in the
composite endpoint between the ﬁrst and second quartiles
(p ¼ 0.14) (Fig. 3).
ROC curve analysis demonstrated that PRU values were
signiﬁcant discriminators of major events at 1 year, with an
area under the curve of 0.883 (95% CI: 0.811 to 0.954;
p < 0.0001), and indicated that PRU 234 was the optimal
cutoff value for the prediction of the primary composite
outcome, demonstrating a 92.1% sensitivity and a 84.2%
speciﬁcity (Fig. 4). The test’s positive and negative predictive
values were 67.3% and 93.9%, respectively.
According to subgroup univariate analysis, CLI (78.4%
vs. 46.9%; p < 0.0001), chronic renal disease (70.6%vs. 42.9%; p ¼ 0.002), and diabetes mellitus (21.6% vs.
4.1%; p ¼ 0.004) were related to an increased rate of
HPR (PRU value above the cutoff of 234). The majority
of the patients enrolled were receiving statin therapy (76%)
for the treatment of hyperlipidemia. Statistical analysis did
not detect any association between statin use and HPR or
outcomes.
Cox multivariate stepwise backward logistic regression
analysis indicated that a PRU value above the cutoff value of
Figure 4 ROC Analysis
Receiver-operating characteristic (ROC) curve indicating the optimal cutoff value of
platelet (P2Y12) reaction units (PRU) that predicts adverse clinical outcomes.
Figure 5 Event-Free Survival and Cutoff Value
Cox regression analysis adjusted plots of event-free survival stratiﬁed according to
the platelet (P2Y12) reaction units (PRU) cutoff value.
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2432234 was the only independent predictor of increased adverse
clinical events, with an adjusted hazard ratio of 16.94 (95%
CI: 5 to 55; p < 0.0001) (Fig. 5). The Cox regression
model–adjusted plots, as stratiﬁed according to the quartile
distribution of PRU, are demonstrated in Fig. 6. None of
the remaining analyzed variables were shown to affect the
primary outcome measure. In this study, the ﬁrst event was
noted nearly 3 months after the procedure, and no acute or
subacute thromboischemic events were noted up to 30 days
post-procedure. However, the majority of TVR events
occurred due to reocclusion of the target vessel (22 of 36
[61.1%]). In 11 of the 36 femoropopliteal TVR cases
(30.5%), additional BTK interventions were performed to
improve runoff (1 intervention in the ﬁrst quartile, 1 in the
second, 5 in the third, and 4 in the fourth). Overall, 4
bleeding events (4.0%) requiring further intervention were
noted (3 of 49 patients in the ﬁrst 2 quartiles with a PRU
below the cutoff value, and 1 of 51 patients in the fourth
quartile with PRU above the cutoff value [6.1% vs. 2.0%,
respectively; p ¼ 0.14]). Speciﬁcally, there was 1 case of
major retroperitoneal bleeding (1%) in a patient in the
second quartile with a PRU of 194 who required transfusion
of 2 U of red blood cells due to a hemoglobin drop of nearly
4 g/dl. He was discharged from the hospital 48 hours after
the procedure. There were 2 pseudoaneurysms (2%) (1 each
in patients in the ﬁrst and second quartiles, with PRU values
of 90 and 185, respectively), both successfully managed with
percutaneous ultrasound–guided thrombin injection. Finally,
bleeding through the puncture site resulting in a large groinFigure 6 Quartile-Based Event-Free Survival
Cox regression analysis adjusted plots of event-free survival stratiﬁed according to
the quartile distribution of platelet (P2Y12) reaction units (PRU).
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2433hematoma occurred in 1 patient (1%) with a PRU of 310
and was managed with prolonged manual compression.
When excluding TVR events, there were no signiﬁcant
differences in the rest of the adverse clinical events in
patients with PRU values below the cutoff value compared
to those with PRU values above the cutoff value. One
ischemic stroke resulting in death and 1 major amputation
occurred, each in patients with PRU values 234 (p ¼ 0.16
in each case). No other complications were observed.
Discussion
Inhibition of platelet aggregation using oral antiplatelet
therapy with clopidogrel is widely used following endovas-
cular or surgical peripheral revascularization procedures
(3,19). Although numerous trials have reported the clinical
signiﬁcance of on-treatment HPR following PCI (18), data
demonstrating the correlation of platelet responsiveness with
clinical outcomes of PEPs are scarce. Moreover, the optimal
PRU cutoff value of platelet inhibition inﬂuencing outcomes
of peripheral angioplasty or stenting has not been recog-
nized. This study demonstrated that an inadequate response
to clopidogrel, identiﬁed using point-of-care testing just
prior to the procedure, is a new strong independent predictor
of reduced event-free survival, adversely inﬂuencing midterm
clinical outcomes of peripheral angioplasty and stenting. The
multivariate Cox regression analysis demonstrated that
patients receiving clopidogrel with residual platelet reactivity
above the optimal cutoff value had an unexpected almost
17-fold increased risk for clinical events (Figs. 5 and 6).
The authors performed a quartile-distribution analysis
due to the progressively increasing event rate observed across
PRU quartiles, as previously reported (22). According to our
results, the 50 patients included in the ﬁrst 2 quartiles (PRU
between 55 and 242) demonstrated a signiﬁcantly lower
cumulative clinical events rate compared to the 50 patients
included in the third and fourth quartiles (PRU between 244
and 426) at 1-year follow-up.
ROC analysis identiﬁed PRU 234 as the optimal cutoff
value to predict clinical outcomes of infrainguinal angio-
plasty or stenting. This was in line with the majority of the
coronary studies, as according to a recent meta-analysis,
a PRU value 230 was associated with a signiﬁcant
twofold increased rate of the composite endpoint of death,
myocardial infarction, and stent thrombosis (24). Compared
to the results reported from several coronary studies, in the
PRECLOP study, the speciﬁc point-of-care assay demon-
strated analogous sensitivity and speciﬁcity (92.1% and
84.2%, respectively) and positive and negative predictive
values, validating its accuracy in predicting clinical outcomes
of PAD treatment (16,22,24). The 93.9% negative predic-
tive value of the test indicates that patients with a PRU
below the cutoff value are unlikely to experience a clinical
adverse event up to 1 year after the revascularization
procedure, regardless of the technique or endovascular device
used, the characteristics and location of the lesion, and theclinical stage of the disease, whereas the 67.3% positive
predictive value points out that nearly three fourths of the
patients with a PRU above the cutoff value could develop
recurrent clinical symptomatology within 1 year following
the procedure. Notably, although the cumulative 1-year
event rate of the entire cohort was 38%, a subgroup anal-
ysis indicated that in patients with a PRU below the cutoff
value, the cumulative clinical events rate dropped to 6.1%
(3 of 49) compared to 68.6% (35 of 51) in patients with
a PRU above the cutoff value.
The events noted during follow-up were mainly clinically
driven endovascular re-intervention procedures, as 1 death
and 1 major above-the-knee amputation were reported.
Although the hypothesis was generated on the basis of current
evidence, the obvious correlation between disease recurrence
and on-treatment HPR suggests the need for long-term
antiplatelet therapy not only to reduce thromboembolic
cardiovascular events but also to limit the phenomenon
of symptomatic vascular restenosis following PEPs. No
procedure-related deaths were noted, and bleeding events
were rare, with no signiﬁcant difference in bleeding rates
between the groups with PRU values below and above the
cutoff value, demonstrating the safety proﬁle of standard
clopidogrel therapy before, during, and following peripheral
angioplasty and stenting. Moreover, all bleeding events were
puncture related and could have presumably occurred even
if antiplatelet therapy was not prescribed, and no drug-related
side effects were noted to discourage the continuation of
clopidogrel.
Study limitations. Limitations of this study include the
single-center design, and the small number of patients
investigated might generate an inherent bias and did not
enable the assessment of the correlation between PRU and
bleeding events. Furthermore, the generally small numbers
of events made it difﬁcult to achieve fully adjusted models.
Larger trials are required to further evaluate the results
reported herein and to provide a therapeutic window for
clopidogrel in the ambit of peripheral endovascular treat-
ment (25). Additionally, on-treatment platelet reactivity was
assessed only with point-of-care testing, and no standard
laboratory method was available as a control. Nonetheless,
the VerifyNow assay was previously used in several PCI
studies and is currently widely accepted as an accurate test of
on-treatment platelet reactivity, and absolute PRU values
measured by the VerifyNow point-of-care assay have been
correlated with the results of laboratory-assessed ADP-
induced optical aggregometry (12,13,18,23–27). Finally, this
study investigated platelet responsiveness in elective proce-
dures in which all subjects were treated with a maintenance
dose of clopidogrel 75 mg once daily for at least 1 month
prior to the index procedure. Hence, the effect of a peri-
procedural loading dose of clopidogrel (300 to 600 mg) was
not studied. However, on the basis of clopidogrel pharma-
cokinetics and on previously reported data from coronary
trials, the authors can only speculate that the results should
not differ signiﬁcantly (9,16–18).
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authors advocate the use of the speciﬁc point-of-care testing
to detect HPR during clopidogrel treatment to recognize
patients at higher risk for clinical adverse events and to
encourage individualized, alternative antiplatelet regimens,
such as a doubled clopidogrel dose or newer antiplatelet
drugs (e.g., prasugrel, ticagrelor), with the aim of improving
clinical outcomes after PEPs.
Conclusions
The PRU cutoff value optimal for predicting clinical
outcomes of peripheral angioplasty and stenting, assessed
with VerifyNow point-of-care testing, was 234. Patients
with on-treatment HPR experienced signiﬁcantly more
clinical events, and a PRU above the cutoff value was
identiﬁed as a strong independent predictor of decreased
event-free survival at 1-year follow-up.
Acknowledgments
The authors thank their department’s nursing staff and, in
particular, Athina Noukou, Maria Filipopoulou, Stamatia
Mpekou, Theodora Karitinou, Fotini Konaki, and Athina
Zisi, for their valuable contributions in blood sampling, data
recording, and patient care.
Reprint requests and correspondence: Dr. Stavros Spiliopoulos,
Department of Interventional Radiology, Patras University
Hospital, 26500 Rio, Greece. E-mail: stavspiliop@upatras.gr.
REFERENCES
1. Jennings LK. Mechanisms of platelet activation: need for new strategies
to protect against platelet-mediated atherothrombosis. Thromb Hae-
most 2009;102:248–57.
2. Gawaz M, Langer H, May AE. Platelets in inﬂammation and
atherogenesis. J Clin Invest 2005;115:3378–84.
3. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus
aspirin alone for the prevention of atherothrombotic events. N Engl J
Med 2006;354:1706–17.
4. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis
of randomised trials of antiplatelet therapy for prevention of death,
myocardial infarction, and stroke in high risk patients. BMJ 2002;
324(7329):71–86.
5. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of
drug-eluting stent thrombosis during and after discontinuation of
thienopyridine treatment. Circulation 2007;116:745–54.
6. Stone GW, Ellis SG, Colombo A, et al. Offsetting impact of throm-
bosis and restenosis on the occurrence of death and myocardial
infarction after paclitaxel-eluting and bare metal stent implantation.
Circulation 2007;115:2842–7.
7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. Variability in indi-
vidual responsiveness to clopidogrel: clinical implications, management,
and future perspectives. J Am Coll Cardiol 2007;49:1505–16.
8. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet
responsiveness to clopidogrel among 544 individuals. J Am Coll
Cardiol 2005;45:246–51.
9. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is
associated with increased risk of recurrent atherothrombotic events in
patients with acute myocardial infarction. Circulation 2004;109:
3171–5.10. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients
and recurrent events post-stenting results of the prepare post-stenting
study. J Am Coll Cardiol 2005;46:1820–6.
11. Serebruany VL, Oshrine BR, Malinin AI, et al. Noncompliance in
cardiovascular clinical trials. Am Heart 2005;150:882–6.
12. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel:
a review of the evidence. J Am Coll Cardiol 2005;45:1157–64.
13. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet
function tests in predicting clinical outcome in patients undergoing
coronary stent implantation. JAMA 2010;303:754–62.
14. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of
a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with
clopidogrel. Methods Find Exp Clin Pharmacol 2006;28:315–22.
15. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition
after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the
VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res
2007;119:277–84.
16. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic signiﬁcance of
post-clopidogrel platelet reactivity assessed by a point-of-care assay on
thrombotic events after drug-eluting stent implantation. Eur Heart J
2008;29:992–1000.
17. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and
nonfatal myocardial infarction in acute coronary syndrome patients
receiving coronary stenting are predicted by residual platelet reactivity
to ADP detected by a point-of-care assay: a 12-month follow-up.
Circulation 2009;119:237–342.
18. Bonello L, Tantry US, Marcucci R, et al., for the Working Group
on High On-Treatment Platelet Reactivity. Consensus and future
directions on the deﬁnition of high on-treatment platelet reactivity
to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–33.
19. Altenburg A, Haage P. Antiplatelet and anticoagulant drugs in inter-
ventional radiology. Cardiovasc Intervent Radiol 2012;35:30–42.
20. Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral
arterial interventions with mono or dual antiplatelet therapydthe
MIRROR study: a randomised and double-blinded clinical trial. Eur
Radiol 2012;22:1998–2006.
21. Alexopoulos D, Xanthopoulou I, Tsigkas G, et al. Predictors of
high on-treatment platelet reactivity early after clopidogrel loading
in ST-elevation myocardial infarction. Circ J 2012;76:2183–7.
22. Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A,
Di Sciascio G. Point-of-care measurement of clopidogrel responsive-
ness predicts clinical outcome in patients undergoing percutaneous
coronary intervention. Results of the ARMYDA-PRO (Antiplatelet
therapy for Reduction of MYocardial Damage during Angioplasty-
Platelet Reactivity Predicts Outcome) Study. J Am Coll Cardiol
2008;52:1128–33.
23. InterSociety Consensus for the Management of Peripheral Arterial
Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33 Suppl 1:S63.
24. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on
clinical outcomes after percutaneous coronary intervention. A collabo-
rative meta-analysis of individual participant data. J Am Coll Cardiol
2011;58:1945–54.
25. Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G. Usefulness of
platelet response to clopidogrel by point-of-care testing to predict
bleeding outcomes in patients undergoing percutaneous coronary
intervention (from the Antiplatelet Therapy for Reduction of
Myocardial Damage During Angioplasty-Bleeding Study). Am J
Cardiol 2011;107:995–1000.
26. Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J Suppl
2008;10 Suppl A:A28–34.
27. Van Werkum JW, Van der Stelt CA, Seesing TH, Hackeng CM,
Ten Berg JM. A head-to-head comparison between the VerifyNow
P2Y12 assay and light transmittance aggregometry for monitoring the
individual platelet response to clopidogrel in patients undergoing
elective percutaneous coronary intervention. J Thromb Haemost 2006;
4:2516–8.Key Words: angioplasty - antiplatelet therapy - clopidogrel -
femoropopliteal - high platelet reactivity - peripheral endovascular
procedures - stenting.
